1. Home
  2. LOOP vs BOLD Comparison

LOOP vs BOLD Comparison

Compare LOOP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$1.01

Market Cap

58.1M

Sector

Industrials

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$1.19

Market Cap

26.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LOOP
BOLD
Founded
2010
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
26.9M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
LOOP
BOLD
Price
$1.01
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
74.5K
133.7K
Earning Date
01-15-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,112,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$41.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10901.98
N/A
52 Week Low
$0.85
$1.00
52 Week High
$2.29
$3.12

Technical Indicators

Market Signals
Indicator
LOOP
BOLD
Relative Strength Index (RSI) 46.77 52.99
Support Level $0.95 $1.15
Resistance Level $1.04 $1.24
Average True Range (ATR) 0.06 0.08
MACD 0.02 0.00
Stochastic Oscillator 71.73 36.00

Price Performance

Historical Comparison
LOOP
BOLD

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: